Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PYXS by emailGet an email when PYXS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PYXS, unsubscribe in one click. Privacy
📣 What PYXS Says Is Next
second half of 2027 · “Additional data evaluating initial durability and selection of the recommended Phase 3 dose (RP3D) for the 1L combination are expected in the second half of 2027.”
Company press release, Sep 9, 2026 · SEC filing
fourth quarter of 2026 · “Combination with KEYTRUDA® (pembrolizumab) Pyxis Oncology expects to report updated data from the ongoing Phase 1/2 combination dose escalation study of MICVO and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for 1L R/M HNSCC patients in the fourth quarter of 2026.”
Company press release, Sep 9, 2026 · SEC filing
mid-2027 · “Pyxis Oncology plans to initiate the study in mid-2027 following alignment with the FDA on dose selection.”
Company press release, Sep 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PYXS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PYXS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.